Allen Xue

6.4k total citations · 4 hit papers
40 papers, 2.6k citations indexed

About

Allen Xue is a scholar working on Oncology, Surgery and Immunology. According to data from OpenAlex, Allen Xue has authored 40 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 13 papers in Surgery and 13 papers in Immunology. Recurrent topics in Allen Xue's work include CAR-T cell therapy research (26 papers), Lipoproteins and Cardiovascular Health (13 papers) and Biosimilars and Bioanalytical Methods (10 papers). Allen Xue is often cited by papers focused on CAR-T cell therapy research (26 papers), Lipoproteins and Cardiovascular Health (13 papers) and Biosimilars and Bioanalytical Methods (10 papers). Allen Xue collaborates with scholars based in United States, Netherlands and Australia. Allen Xue's co-authors include Scott M. Wasserman, Robert C. Scott, David Sullivan, Evan A. Stein, John M. Rossi, Adrian Bot, Sattva S. Neelapu, Frederick L. Locke, Ricardo Dent and Armin Ghobadi and has published in prestigious journals such as JAMA, Circulation and Nature Medicine.

In The Last Decade

Allen Xue

39 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

2017 463 citations Frederick L. Locke, Sattva S. Neelapu et al. Molecular Therapy profile →
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance

2014 421 citations Erik S.G. Stroes, David Colquhoun et al. Journal of the American College of Cardiology profile →
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients

2012 369 citations David Sullivan, Anders Olsson et al. JAMA profile →
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

2014 281 citations Frederick J. Raal, Robert P. Giugliano et al. Journal of the American College of Cardiology profile →

Peers

Countries citing papers authored by Allen Xue

Since Specialization

Citations

This map shows the geographic impact of Allen Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allen Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allen Xue more than expected).

Fields of papers citing papers by Allen Xue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allen Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allen Xue. The network helps show where Allen Xue may publish in the future.

Co-authorship network of co-authors of Allen Xue

This figure shows the co-authorship network connecting the top 25 collaborators of Allen Xue. A scholar is included among the top collaborators of Allen Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allen Xue. Allen Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA 2023 ·HemaSphere ·Jason R. Westin, Caron A. Jacobson, Julio C. Chávez, Anna Sureda, Franck Morschhauser, Bertram Glaß, Michael Dickinson, Andrew Davies, Ian W. Flinn, David G. Maloney, Martine E.D. Chamuleau, Michael Tees, Allen Xue, Shilpa Shahani, (unknown), (unknown), (unknown), Marco Schupp, Harry Miao, Elizabeth Rich	1
2	Curative Potential of Axicabtagene Ciloleucel (Axi-Cel): An Exploratory Long-Term Survival Assessment in Patients with Refractory Large B-Cell Lymphoma from ZUMA-1 2023 ·Blood ·Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, (unknown), Jaeyeon Kim, Harry Miao, Allen Xue, Yan Zheng, Frederick L. Locke	1
3	Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial 2021 ·Transplantation and Cellular Therapy ·Michael Wang, John M. Rossi, Javier Muñoz, André Goy, Frederick L. Locke, Patrick M. Reagan, Caron A. Jacobson, Brian T. Hill, Houston Holmes, Samantha Jaglowski, Weimin Peng, Lianqing Zheng, Xiang Fang, Allen Xue, Ioana Kloos, Adrian Bot	2
4	Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma 2020 ·Nature Medicine ·Jennifer N. Brudno, Norris Lam, Danielle Vanasse, Yueh-wei Shen, Jeremy J. Rose, John M. Rossi, Allen Xue, Adrian Bot, Nathalie Scholler, Lekha Mikkilineni, Mark Roschewski, Robert M. Dean, Raúl E. Cachau, Philippe Youkharibache, Rashmika Patel, Brenna Hansen, David F. Stroncek, Steven A. Rosenberg, Ronald E. Gress, James N. Kochenderfer	228
5	Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy 2020 ·Haematologica ·Ranjit Nair, (unknown), Faustine Lhomme, Anthony Le Bras, (unknown), John M. Rossi, Marika Sherman, Allen Xue, A. Kerber, (unknown), Linda Chi, Sudhakar Tummala, Sattva S. Neelapu, Roch Houot	25
6	CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel 2019 ·Blood ·Sattva S. Neelapu, John M. Rossi, Caron A. Jacobson, Frederick L. Locke, David B. Miklos, Patrick M. Reagan, Scott J. Rodig, Lazaros J. Lekakis, Ian W. Flinn, Lianqing Zheng, Francesca Milletti, (unknown), Allen Xue, Vicki Plaks, Jaeyeon Kim, Adrian Bot	51
7	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma breakdown → 2017 ·Molecular Therapy ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y. Go	463
8	Zuma-6: Phase 1-2 multicenter study evaluating safety and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab in patients with refractory diffuse large b-cell lymphoma (DLBCL). 2017 ·Journal of Clinical Oncology ·Frederick L. Locke, Jason R. Westin, David B. Miklos, Alex F. Herrera, Caron A. Jacobson, Lillian Lee, John M. Rossi, Adrian Bot, Allen Xue, Lynn Navale, Jeff Aycock, Jeffrey S. Wiezorek, Zachary Roberts	9
9	PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI‐CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI‐CEL) 2017 ·Hematological Oncology ·Sattva S. Neelapu, John M. Rossi, Frederick L. Locke, Allen Xue, Marc Better, (unknown), Armin Ghobadi, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick M. Reagan, Lynn Navale, William Y. Go, Jeff Wiezorek, Adrian Bot	2
10	REDUCTION IN LIPOPROTEIN (A) WITH EVOLOCUMAB: ELUCIDATION OF THE ROLE OF THE LDL RECEPTOR FROM CLINICAL TRIALS AND IN-VITRO MODELS 2016 ·Journal of the American College of Cardiology ·Frederick J. Raal, Robert P. Giugliano, Marc S. Sabatine, Michael J. Koren, Dirk Blom, Nabil G. Seidah, Narimon Honarpour, Armando Lira Pineda, Allen Xue, Simon Jackson, (unknown), Matthew Peach, Ransi Somaratne, Scott M. Wasserman, Robert C. Scott, Evan A. Stein	1
11	Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study 2016 ·Cardiovascular Drugs and Therapy ·Leslie Cho, Michael Rocco, David Colquhoun, David Sullivan, Robert S. Rosenson, Ricardo Dent, Allen Xue, Robert C. Scott, Scott M. Wasserman, Erik S.G. Stroes	15
12	Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. 2016 ·Journal of Clinical Oncology ·James N. Kochenderfer, Robert Somerville, Tangying Lu, Victoria Shi, James C. Yang, Richard M. Sherry, Christopher A. Klebanoff, Udai S. Kammula, Stephanie L. Goff, Adrian Bot, John M. Rossi, Marika Sherman, Arianne Perez, Allen Xue, Tatyana Feldman, Jonathan W. Friedberg, Mark Roschewski, Steven A. Feldman, Lori McIntyre, Steven A. Rosenberg	12
13	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial 2016 ·Clinical Cardiology ·Steven E. Nissen, Ricardo E. Dent‐Acosta, Robert S. Rosenson, Erik S.G. Stroes, Naveed Sattar, David Preiss, G.B. John Mancini, Christie M. Ballantyne, Alberico L. Catapano, (unknown), Evan A. Stein, Allen Xue, Scott M. Wasserman, (unknown), Paul D. Thompson, (unknown)	30
14	A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk 2015 ·The American Journal of Cardiology ·Arihiro Kiyosue, Narimon Honarpour, Christopher E. Kurtz, Allen Xue, Scott M. Wasserman, Atsushi Hirayama	91
15	Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy 2014 ·Clinical Cardiology ·Leslie Cho, Michael Rocco, David Colquhoun, David Sullivan, Robert S. Rosenson, Ricardo Dent, Allen Xue, Robert C. Scott, Scott M. Wasserman, Erik S.G. Stroes	25
16	Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) breakdown → 2014 ·Journal of the American College of Cardiology ·Frederick J. Raal, Robert P. Giugliano, Marc S. Sabatine, Michael J. Koren, Gisle Langslet, Harold Bays, Dirk Blom, Mats Eriksson, Ricardo Dent, Scott M. Wasserman, Fannie Huang, Allen Xue, Moetaz Albizem, Robert C. Scott, Evan A. Stein	281
17	Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance breakdown → 2014 ·Journal of the American College of Cardiology ·Erik S.G. Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert S. Rosenson, Gerald F. Watts, Éric Bruckert, Leslie Cho, Ricardo Dent, Beat Knüsel, Allen Xue, Robert C. Scott, Scott M. Wasserman, Michael Rocco	421
18	CLINICAL PROFILE OF STATIN INTOLERANCE IN THE PHASE 3 GAUSS-2 STUDY 2014 ·Canadian Journal of Cardiology ·(unknown), Monica Rocco, David Colquhoun, David Sullivan, Robert S. Rosenson, Ricardo Dent, Allen Xue, Robert C. Scott, Scott M. Wasserman, Erik S.G. Stroes	2
19	Abstract 12621: Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance 2013 ·Circulation ·Evan A. Stein, Ransi Somaratne, (unknown), Fernando Civeira, Danielle Sullivan, Gerald F. Watts, Robert Weiss, Leon A. Simons, (unknown), Allen Xue, Russell Scott, Scott M. Wasserman, Matti J. Tikkanen	2
20	Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients breakdown → 2012 ·JAMA ·David Sullivan, Anders Olsson, Robert C. Scott, Jae Bum Kim, Allen Xue, Val Gebski, Scott M. Wasserman, Evan A. Stein	369

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact